Markets

Insider Trading

Hedge Funds

Retirement

Opinion

12 Cheap Chinese Stocks to Buy According to Hedge Funds

Page 1 of 11

In this article, we will look at the 12 Cheap Chinese Stocks to Buy According to Hedge Funds.

Trump’s Back and China’s Stimulus Lags

Trump is back as the President of the United States and China’s stimulus plans have let down investors, which has created more economic uncertainty regarding China. China is trying to fix its economy and Trump’s comeback to the White House means steep tariffs for Chinese-made goods. In his first term, President-elect Donald Trump imposed tariffs up to 25% on Chinese goods, initiating a trade war between two global giants. Trump’s second stint in the office is expected to imply tariffs as high as 60% on Chinese-made goods.

On the other hand, China’s stimulus of $1.5 trillion or nearly 10 billion yuan to back its economy doesn’t seem to appeal the investors. China’s stimulus has come at a time when the economy is struggling badly and there are potential tariff threats from the new U.S. administration. In addition to that, overseas companies are drawing their money out of China as the growth outlook seems gloomier. In the first nine months of 2024, foreign direct investment (FDI) slid nearly $13 billion. According to China’s Administration of Foreign Exchange, the FDI outflows exceeded $8.1 billion in Q3, potentially leading to a net FDI outflow for the first time since 1990. This shows that investors are still pessimistic regarding China’s economic reforms aimed at stabilizing growth.

READ ALSO Jim Cramer’s Latest Lightning Round: 11 Stocks to Watch and Jim Cramer on AMD and Other Stocks

Other Problems with the Chinese Economy

The consumer price inflation (CPI) in October eased to 0.3% year-over-year compared to an expected 0.4%, while the producer price index (PPI) dropped by 2.9% year-over-year in October, slightly widening from the 2.8% decline observed in September 2024. Following the U.S. elections and China’s lower-than-expected inflation outcome, UBS has lowered China’s 2025 GDP growth estimate to 4% from the 4.5% it made in October. The Swiss Bank anticipates the GDP growth for 2026 to be also considerably lower.

What Could Happen in the Short-Term and the Long-term?

With Trump’s victory and the news regarding sparking expectations of steep tariffs, U.S. importers are expected to rush to front-load goods from China before the Presidential inauguration in January 2025. This could potentially lead to cost increases and deliver a surprising push to Chinese exports.

In the long run, analysts expect Trump’s tariff policy’s impact on the Chinese economy would be modest. However, the additional tariffs could hit exports and lead to a higher fiscal deficit or currency depreciation for China. Economists at Capital Economics project that the direct impact of large U.S. tariffs on China would be less than 0.5% of its GDP. The reason for this can be exporters finding alternative routes via other countries and also receiving support from depreciation of the yuan.

The Hang Seng Index has plunged more than 4% over the last five days, as of November 15, while the CSI 300 index has plummeted by nearly 2.50% in the last five days and is up by almost 3% in the last month. We can see the mixed reaction of the market considering the recent events.

With that, let’s take a look at the 12 cheap Chinese stocks to buy according to hedge funds.

zhu difeng/Shutterstock.com

Our Methodology

To find the 10 Cheap Chinese Stocks to Buy According to Hedge Funds, first, we used stock screeners and shortlisted Chinese stocks listed on US exchanges with a market capitalization of more than $1 billion and a forward P/E ratio of less than 15, as of November 15. We narrowed down our selection to 10 stocks that were the most widely held by institutional investors and ranked them in ascending order of the number of hedge funds that have stakes in them, as of Q2 of 2024.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

12 Cheap Chinese Stocks to Buy According to Hedge Funds

12. Autohome Inc. (NYSE:ATHM)

Number of Hedge Fund Holders: 16

Forward P/E Ratio: 12.85

Autohome Inc. (NYSE:ATHM) is a holding firm that runs one of the leading online retail platforms for automobiles. The company has access to a wide customer base and the data is used to generate leads and assist in advertising services. Lead generation services allow Autohome dealer subscribers to create their online stores, while media services assist with marketing solutions in connection with brand promotion, new model releases, and sales promotion. The majority of the operations of the company are in Mainland China.

Based on customer needs, Autohome’s online automobile platform provides accurate and effective customized content and commercial offerings. During Q3 2024, the company’s average mobile daily active users increased by 5.6% year-over-year, crossing 70 million users. Autohome’s new professional content and product mix have strengthened its differentiated competitive advantages, leading to a solid improvement in traffic. The company organized over 500 offline auto shows in low-tier markets which helped in consumer engagement. The company’s initiatives such as “Hundred Cities ‘Trade-in for New’ Car-Buying Festival” bring a competitive edge to the company’s offering in the sector through higher consumer engagement.

In Q3, Autohome Inc. (NYSE:ATHM) improved its revenue by 3.1% year-over-year from the online marketplace and other segments. The company is taking long-term initiatives to continue its dominance in the competitive automobile market in China. Autohome expanded its new retail business into lower-tier cities, introducing a network of over 50 stores in the last quarter. One of the keys to Autohome’s successful initiatives is its collaboration with Ping An Group. The company plans to utilize Ping An Group’s off-line resources and aftermarket service capabilities to have an upper edge in the online auto industry.

11. iQIYI, Inc. (NASDAQ:IQ)

Number of Hedge Fund Holders: 17

Forward P/E Ratio: 7.32

iQIYI, Inc. (NASDAQ:IQ) is China’s leading online entertainment services company that is often referred to as the “Netflix of China.” iQIYI provides original content such as movies, television shows, and a variety of other genres. Some of the well-known shows hosted by the company include The Lost Tomb, The Mystic Nine, Burning Ice, Qipa Talk, and The Rap of China, among others. iQIYI’s over-the-top streaming (OTT) service has a similar business model to Netflix which is subscription-based. The company charges a monthly fee of $6.99 for Standard and $9.99 for Premium offering.

iQIYI has a subscriber base of over 100 million and has more than 400 million monthly active users. iQIYI, Inc. (NASDAQ:IQ) is continuing to expand into new markets to enhance its future growth. The company’s expansion policy has reaped fruits as the annual membership revenue soared notably in markets including Hong Kong and the U.K.

However, the company fell short in the second quarter of 2024 mainly due to fluctuation in iQIYI’s content slate performance. In Q2, the company posted a 5% year-over-year drop in revenue. IQ seems to be a cheap stock as it has a forward P/E of just over 7 and is trading at a discount of almost 38% to its sector median of 14.07%.

Page 1 of 11

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

Penicillin Changed the World. This Drug Could Too

This Clinical-stage Biotech Company is Taking a Revolutionary Approach to Eradicating Many Respiratory Viruses Including a single drug to treat COVID, RSV, FLU and even Monkey-pox!

This is a clinical-stage, global leader in broad-spectrum antiviral nanomedicines who is developing therapeutic drugs that work safely and effectively, even against emerging variants!

A novel broad-spectrum antiviral

NV-387,  a drug that  treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, the company has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.

Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because  no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.

Click to continue reading…